MAKATI MEDICAL CENTER DEPARTMENT OF MEDICINE MEDICAL GRANDROUNDS

Slides:



Advertisements
Similar presentations
LINEE GUIDA, KDIGO E DIALISI PERITONEALE
Advertisements

Hypoparathyroidism: the hormone replacement therapy is close
History of Present Illness 9 months Terminal pain during urination UTI – cefuroxime 250mg/5mL BIDx7 days 6 months Fever and loss of appetite; U/A - WBC:
General Data R.G. 2 years 4 months (May 22, 2008) Male Filipino Roman Catholic Sampaloc, Manila Informant: Mother Reliability: Good.
Upper GI Bleeding Case 2 Alonzo, Amaro, Amolenda, Anacta, Andal.
Alonzo.Amaro.Amolenda Anacta.Andal. Beginning Data  Male, 45 year old  Chief Complain: Severe Abdominal Pain.
Objective To present a case of a Hemophagocytic Lymphohistiocytosis (HLH)
Bone Disease in Renal Failure Dr Anne Kleinitz and Dr Cherelle Fitzclarence
Management of Secondary and Tertiary Hyperparathyroidism - Joint Hospital Grandround Henry Joeng Department of Surgery United Christian Hospital,
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
Mario Cozzolino, MD, PhD NUOVE ACQUISIZIONI NELLA TERAPIA DELL’IPERPARATIROIDISMO SECONDARIO IN DIALISI PERITONEALE XV CONVEGNO del Gruppo di Studio di.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Nephrology Grand Rounds 5/13/08. Refractory Hyperparathyroidism Brad Weaver.
PARATHYROID HORMONE, HYPERPARATHYROIDISM CKD, & PTH ASSAYS David Plaut & Shanti Narayanan Summer, 2012.
Finishing Renal Disease Aging and death. Chronic Renal Failure Results from irreversible, progressive injury to the kidney. Characterized by increased.
Hyperparathyroidism.
Effect of cinacalcet on bone markers in a maintenance haemodialysis patient Solenn Pelletier, MD and Denis Fouque, MD, PhD Hôpital E. Herriot Lyon, France.
Hypercalcemia Hypocalcemia
Calcium Disorders Dr. Sohail Inam Consultant Endocrine & Diabetes Prince Sultan Military Medical City Riyadh.
By Dr. Sana Fatima Instructor, Biochemistry Department.
Parathyroid gland M. Alhashash. Anatomy Physiology.
PARATHYROID BY ALLYRILEY & CODYPRICE PERIOD 7. WHERE The parathyroid is located in the neck. Located behind the thyroid gland Everyone has four parathyroid.
Bone and Mineral Disorders in Chronic Kidney Disease
CALCIUM HOMEOSTASIS Dr. Sumbul Fatma. Calcium Homeostasis Falling.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
Chronic Kidney Disease-Mineral and Bone Disorder
Clinical Pathological Conference Kartikya Ahuja, M.D. Resident Physician Department of Medicine NYU School of Medicine July 20 th, 2007.
An adolescent with bone pain. LYM, 17/M 17 years old boy C/O: –1 month history of scalp lump HPI: –Heel pain –Polydipsia, polyuria, nocturia 1 year.
J.M. 21 y/o female cc: scalp mass. History of Present Illness Slowly enlarging, firm, occasionaly tender mass on R parietoocipital area (3x3cm) Consult.
NYU Medical Grand Rounds Clinical Vignette Verity Schaye MD, PGY-2 February 3, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
1 Parathyroid Gland Dysfunction Excela Health School of Anesthesia.
Li, Henry Winston Li, Kingbherly Lichauco, Rafael Lim, Imee Loren Lim, Jason Morven Lim, John Harold.
Calcium Homeostasis. 99% body calcium in skeleton 0.9 % intracellular 0.1% extracellular 50% bound Mostly albumin (alkalosis) Smaller amount phosphorous.
Dengue Fever with Warning Signs. Objectives To identify warning signs seen in Dengue Fever To manage a case of Dengue Fever with warning signs.
Patient History  TO  14 year old male  Lives in Palau  Right-handed  Informant: Patient, good reliability Chief Complaint: Wrist Injury.
Tertiary hyperparathyroidism & postoperative hypocalcemia Brock Lanier, M.D. MCV/VCU Department of Surgery M&M 12 April
Assessment and management of parathyroid hyperplasia in secondary hyperparathyroidism Mario Meola, MD, PhD University of Pisa, Hospital of Cisanello, Pisa,
Chronic Kidney Disease SERVICE 6. Chronic Kidney Disease Stages 4-5 (GFR
Hypercalcemia Group Members: Joshua Griffith Jennifer Haynes.
New NKF-K/DOQI guidelines Shahrzad Ossareh-M.D. Kidney Disease Outcome Quality Initiative.
NYU Medical Grand Rounds Clinical Vignette Justin Simmons, M.D. Class of /27/2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Interactive Case 4B Matias; Maulion; Medenilla; Medina; Medina; Mejino; Melgarejo; Mendoza, Alvin, Diana and Donn.
ALCARAZ, ALLEGRE, ALMORA, ALONZO, AMARO, AMOLENDA, ANACTA, ANDAL, ANG, J.
Vitamin D, Rickets and Osteoporosis
Hypercalcemia B 陳名揚. Etiology BONE RESORPTION CALCIUM ABSORPTION MISCELLANEOUS CAUSES.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
 IR  45 years old, female  Right handed  Manila  Chief complaint: purulent discharge from surgical wound.
History and PE Fiona Javelosa. The Curious Case of John Dick Group 3 Clinical Clerk Batch 2012 SY
1 MGR 내분비 대사 내과 R2 황연희. 2 주소 전신적인 무기력증 발병시기 : 약 7 개월 전 현병력 특이 병력과 약물 복용력 없는 62 세 여자 환자로 7 개월 전부터 쉽게 지치고, 일상생활 유지 못할 정도로 전신 무기력감 지속되어 건강검진 시행 받았으며 당시 혈청.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Surgical Treatment of Hyperparathyroidism in Patients.
Primary Hyperparathyroidism presenting with Pancreatitis Prof. Aasem Saif MD, MRCP(UK), FRCP(Edin) Workshop A (Calcium and Bone) Friday 25 October 2013.
Parathyroid Gland & Calcium Metabolism
Case Presentation Jung Hyun Seo Department of Internal Medicine Catholic University of Daegu School of Medicine School of Medicine.
Oral Phosphate Binders in Patients with Kidney Failure
Arm Injury A Case Discussion
Parathyroid Gland & Calcium Metabolism
Endocrine Disorders Parathyroid Gland
Drugs Affecting Calcium Levels and Bone Mineralization
Sergey V. Veretennikov and Michael J. Campbell, MD
II. The Family CP A. Introduction.
Department of Nephrology- Ain Shams University, Cairo, Egypt
The ECHO Observational Study
PARATHYROID AND CALCIUM HOMEOSTASIS
Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.
Dialysis Options: What is the Best Choice for You. Ana C
Presentation transcript:

MAKATI MEDICAL CENTER DEPARTMENT OF MEDICINE MEDICAL GRANDROUNDS Ma. Melmar S. Anicoche, M.D. April 29, 2010

Objectives To discuss the effect of Chronic Kidney Disease (CKD) on calcium-phosphorus metabolism. To discuss biochemical complications after parathyroidectomy.

Patient Profile L.G. , 61/F, from Binan, Laguna DOA: February 12, 2010 Chief complaint: Persistently elevated PTH

History of Present Illness Patient is a diagnosed case of End stage Renal Disease since 2000, on hemodialysis since 2001, three times a week. 2 years PTA 1 year PTA Bone pains, weakness, intermittent abdominal pain iPTH: 914.218 (15-65pg/ml) Normal calcium, elevated phosphorus Impression: tertiary hyperparathyroidism iPTH: 1,528 pg/ml Admission

Personal & Social History: Review of Systems: (-) weight loss, headache, fever, vomiting, chest pain, bowel movement irregularities Past Medical History: s/p Bilateral Ureterolithotomy – 1995 s/p Nephrectomy,left – 1998 s/p ESWL, right – 2000 s/p CVA – 2000 & 2007 Family History: (+) Urolithiasis – parents & siblings Personal & Social History: Nonsmoker Nonalcoholic beverage drinker

BP: 140/70 CR 74 bpm, regular RR 20 cpm T 36.5°C Warm moist skin, no active dermatoses Pink palpebral conjunctivae, anicteric sclerae Supple neck, no palpable lymph nodes, thyroid not enlarged, no masses Symmetric chest expansion, no retractions, clear breath sounds ,AB at 5th LICS MCL, S1 louder than S2 at the apex, S2 louder than S1 at the base, no murmurs Flabby abdomen (+) 9cm incisional scar on left lower quadrant, (+) 6 cm incisional scar on right lower quadrant, NABS, soft, nontender, no organomegaly Full and equal pulses, No cyanosis & edema of extremities MMT: 5/5 on left lower extremity & both upper & lower extremities, 3/5 left upper extremity; slight limitation of motion on all extremities 6

Salient Features 61/F Known case of End Stage Renal Disease for 10 years, on hemodialysis Bone pains, weakness and abdominal pain Elevated iPTH & phosphorus, normal calcium

Impression: Tertiary Hyperparathyroidism

Feedback Mechanisms Restoring Calcium Levels to Normal Serum PTH levels are tightly regulated by a negative feedback loop, and closely regulated by the concentration of serum ionized calcium. A decrease in extracellular calcium triggers an increase in PTH secretion (1) via activation of the calcium sensor receptor on parathyroid cells. PTH, in turn, results in tubular reabsorption of calcium by the kidney, (2) and resorption of calcium from bone (2) and also stimulates renal 1,25 (OH)2D production (3) 1.25 (OH)2D, in turn, acts principally on the intestine to increase calcium absorption (4) Collectively, these homeostatic mechanisms serve to restore serum calcium levels to normal.

Disturbances in mineral & bone metabolism are common in patients with chronic kidney disease. Phosphate retention, which may develop with loss of kidney function, interferes with the ability of patients with CKD to augment the production of 1,25 (OH)2D3 by the kidneys to meet the increased need for this metabolite. Thus, a state of absolute or relative vitamin D deficiency develops, leading to defective intestinal absorption of calcium and impaired calcemic response to PTH. These 2 abnormalities produce hypocalcemia which in turn causes secondary hyperparathyroidism. Hypocalcemia and phosphate retention or hyperphosphatemia are the most important factors responsible for the hyperplasia of the parathyroid glands. Because hypocalcemia may develop early in the course of CKD, hyperactivity of the parathyroid glands is also encountered in the early stages of kidney disease. Indeed, elevated blood levels of PTH may be noted when the GFR falls below 60 mL/min/1.73 m2. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease

Frequency of Measurement of iPTH, Ca & Phos CKD Stage GFR Range iPTH Ca & Phos 3 30 – 59 Every 12 months 4 15 – 29 Every 3 months 5 <15 or dialysis Every month K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease

Target Range of iPTH, Ca & Phos CKD Stage iPTH (pg/ml) Ca (mg/dl) Phos (mg/dl) 3 35 – 70 8.6 – 10.2 2.7 – 4.6 4 70 – 110 5 150 - 300 8.4 – 9.5 3.5 – 5.5 K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease

Outpatient Labs

Pre-operatively, ultrasound of the parathyroid gland was done and it revealed multiple parathyroid gland disease, however, there were only 3 parathyroid glands visualized (right inferior, left superior & left inferior). The aim of the OR was to localize all parathyroid glands and to correct the hyperparathyroidism. Aside from parathyroidectomy, thymectomy was also contemplated, since the thymus is a common site of ectopic parathyroid gland.

1000 800 600 400 200

Day of Surgery

Vitamin D Patients on HD or PD with iPTH >300pg/ml Elevated corrected serum calcium and/or phosphorus levels Patients treated with hemodialysis or peritoneal dialysis with serum levels of intact PTH levels >300 pg/mL (33.0 pmol/L) should receive an active vitamin D sterol (such as calcitriol, alfacalcidol, paricalcitol, or doxercalciferol to reduce the serum levels of PTH to a target range of 150 to 300 pg/ml. The intermittent, intravenous administration of calcitriol is more effective than daily oral calcitriol in lowering serum PTH levels. In patients with corrected serum calcium and/or phosphorus levels above the target range, a trial of alternative vitamin D analogs, such as paricalcitol or doxercalciferol may be warranted. When therapy with vitamin D sterols is initiated or the dose is increased, serum levels of calcium and phosphorus should be monitored at least every 2 weeks for 1 month and then monthly thereafter. The plasma PTH should be measured monthly for at least 3 months and then every 3 months once target levels of PTH are achieved. Patients with CKD who undergo dialysis have reduced plasma levels of 1,25(OH)2D3. This leads to reduced intestinal absorption of calcium (thereby contributing to hypocalcemia) and impaired suppression of the parathyroid gene that initiates the synthesis of PTH. The result is secondary hyperparathyroidism that often progresses. Treatment with calcitriol or another active vitamin D sterol both reduces PTH secretion with resultant improvement of hyperparathyroid bone disease, and improves musculoskeletal symptoms, when these are present.

Hyperparathyroidism Characterized by excessive secretion of PTH Primary Secondary Tertiary Symptoms are due to the hypercalcemia itself The parathyroid glands are primarily responsible for maintaining extracellular calcium concentrations. Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84–amino acid polypeptide hormone. The secretion of parathyroid hormone is regulated directly by the plasma concentration of ionized calcium. Primary hyperparathyroidism is the unregulated overproduction of parathyroid hormone (PTH) resulting in abnormal calcium homeostasis. A single abnormal gland is the cause in 80% of patients. They may arise in hereditary syndromes, such as MEN syndromes. Secondary hyperparathyroidism occurs when partial resistance to the metabolic actions of PTH leads to excessive production of the hormone. Parathyroid gland hyperplasia occurs because resistance to the normal level of PTH leads to hypocalcemia, which, in turn, is a stimulus to parathyroid gland enlargement. PTH hypersecretion, no longer responsive to medical therapy, a state of severe hyperparathyroidism in patients with renal failure, has been referred to as tertiary hyperparathyroidism. This usually requires surgery.

Treatment Options Medical Surgical

Phosphate Binders phosphorus or iPTH levels not controlled despite phosphorus restriction Calcium-based Noncalcium, nonaluminum, nonmagnesium containing Prolonged hyperphosphatemia causes soft-tissue and vascular calcification due at least in part to an increase in calcium-phosphate product and is associated with increased morbidity and mortality. In the case of vascular calcification, hyperphosphatemia exerts a direct calcifying effect on vascular smooth muscle cells. In another study, serum phosphorus levels >6.2 mg/dL (2.00 mmol/L) were associated with increased blood pressure, hyperkinetic circulation, increased cardiac work, and high arterial tensile stress Calcium-based phosphate binders are effective in lowering serum phosphorus levels and may be used as the initial binder therapy. In CKD Patients With Kidney Failure (Stage 5): Both calcium-based phosphate binders and other noncalcium-, nonaluminum-, nonmagnesium-containing phosphate-binding agents (such as sevelamer HCl) are effective in lowering serum phosphorus levels and either may be used as the primary therapy. In dialysis patients who remain hyperphosphatemic (serum phosphorus >5.5 mg/dL [1.78 mmol/L]) despite the use of either of calcium-based phosphate binders or other noncalcium-, nonaluminum-, nonmagnesium-containing phosphate-binding agents, a combination of both should be used. 5.5 The total dose of elemental calcium provided by the calcium-based phosphate binders should not exceed 1,500 mg/day and the total intake of elemental calcium (including dietary calcium) should not exceed 2,000 mg/day. In patients with serum phosphorus levels >7.0 mg/dL (2.26 mmol/L), aluminum-based phosphate binders may be used as a short-term therapy (4 weeks), and for one course only, to be replaced thereafter by other phosphate binders. In such patients, more frequent dialysis should also be considered.

Vitamin D Patients on HD or PD with iPTH >300pg/ml Elevated corrected serum calcium and/or phosphorus levels Patients treated with hemodialysis or peritoneal dialysis with serum levels of intact PTH levels >300 pg/mL (33.0 pmol/L) should receive an active vitamin D sterol (such as calcitriol, alfacalcidol, paricalcitol, or doxercalciferol to reduce the serum levels of PTH to a target range of 150 to 300 pg/ml. The intermittent, intravenous administration of calcitriol is more effective than daily oral calcitriol in lowering serum PTH levels. In patients with corrected serum calcium and/or phosphorus levels above the target range, a trial of alternative vitamin D analogs, such as paricalcitol or doxercalciferol may be warranted. When therapy with vitamin D sterols is initiated or the dose is increased, serum levels of calcium and phosphorus should be monitored at least every 2 weeks for 1 month and then monthly thereafter. The plasma PTH should be measured monthly for at least 3 months and then every 3 months once target levels of PTH are achieved. Patients with CKD who undergo dialysis have reduced plasma levels of 1,25(OH)2D3. This leads to reduced intestinal absorption of calcium (thereby contributing to hypocalcemia) and impaired suppression of the parathyroid gene that initiates the synthesis of PTH. The result is secondary hyperparathyroidism that often progresses. Treatment with calcitriol or another active vitamin D sterol both reduces PTH secretion with resultant improvement of hyperparathyroid bone disease, and improves musculoskeletal symptoms, when these are present.

Calcimimetic Drugs Activate the calcium-sensing receptor and inhibit parathyroid cell function Results in reduction without normalization of PTH levels Reduction & normalization of calcium Cinacalcet

Treatment Options (Surgical) Subtotal or total parathyroidectomy, with or without parathyroid tissue autotransplantation Ablation of parathyroid tissue by direct injection of alcohol Kidney transplantation Effective surgical therapy of severe hyperparathyroidism can be accomplished by subtotal or total parathyroidectomy with parathyroid tissue autotransplantation. All of these methods can result in satisfactory outcomes, and no one technique appears to provide superior outcomes. Accordingly, the choice of procedure may be at the discretion of the surgeons involved. It is important to emphasize that if reimplantation of parathyroid tissue is considered, that a portion of the smallest parathyroid gland, one less likely to have severe nodular hyperplasia, should be reimplanted. Total parathyroidectomy probably is not the procedure of choice in patients who may subsequently receive a kidney transplant, since the subsequent control of serum calcium levels may be problematic in such patients. An alternative to surgical removal of parathyroid glands has recently been introduced in which parathyroid tissue is ablated by direct injection of alcohol into the parathyroid gland under ultrasound guidance. Additional long-term studies with this technique are needed to evaluate its role in long-term therapy. Kidney transplantation can have beneficial effects upon hyperparathyroidism by reversal of hyperphosphatemia and production of 1,25-dihydroxyvitamin D3 by the renal allograft.PTH levels tend to decline over time as the hyperplastic parathyroid glands undergo involution. Within approximately 3 to 6 months after successful transplant, it can be anticipated that 50% of patients with serum creatinine <2.0 mg/dL (177 mmol/L) will have normal levels of intact PTH. Most reports indicate that intact PTH levels usually return to near normal by 1 year after transplant. However, PTH levels can remain above normal, presumably due to persistent parathyroid hyperplasia, as evidenced by other reports.

Parathyroidectomy in Patients with CKD persistent iPTH >800 pg/mL associated with hypercalcemia and/or hyperphosphatemia that are refractory to medical therapy iCa measured every 4 to 6 hours for the first 48 to 72 hours after surgery, and then twice daily until stable. Criteria for adequate excision 50% drop in PTH from the baseline level to the 10-minute postexcision level or 50% drop in PTH from the preexcision level at 10 minutes and a postexcision level below the baseline level. If ionized or corrected total calcium fall below normal (<3.6 mg/dL, calcium gluconate infusion should be initiated at a rate of 1 to 2 mg elemental calcium per kilogram body weight per hour and adjusted to maintain an ionized calcium in the normal range (4.6 to 5.4 mg/dL) A 10-mL ampule of 10% calcium gluconate contains 90 mg of elemental calcium. The calcium infusion should be gradually reduced when the level of ionized calcium attains the normal range and remains stable

Surgical Complications after Parathyroidectomy Nerve damage Bleeding Infection

Biochemical Aberrations in a Dialysis Patient Following Parathyroidectomy Severe hypocalcemia hypophosphatemia hyperkalemia. The abrupt withdrawal of PTH often results in a marked reduction in osteoclast activity. In this setting, osteoblast-mediated bone formation proceeds unopposed, resulting in a dramatic increase in the uptake of calcium and phosphate by bone. Taken together, the combination of decreased bone resorption and improved bone mineralization results in a decrease in serum calcium concentration. The reduced mobilization of phosphate from bone and an increased movement of this divalent anion into bone causes abrupt hypophosphatemia. Cruz, Dinna, et. Al.;American Journal of Kidney Disease, vol 29, No 5 (May) 1997; pp759 - 762

Hungry Bone Syndrome Severe post-operative hypocalcemia despite normal or elevated PTH Occurs in patients who have developed bone disease preoperatively due to a chronic increase in bone resorption induced by high PTH Hypocalcemia is a common problem after parathyroidectomy. This is primarily due to functional or relative hypoparathyroidism, leading to reductions in bone reabsorption and intestinal calcium absorption. The hypocalcemia is generally transient because the degree of bone disease is typically mild and normal parathyroid tissue recovers function quickly (usually within one week), even after long-term suppression. The postoperative hypocalcemia probably results from acute reversal of the PTH-induced contribution of bone to maintenance of the serum calcium concentration. In the high turnover state associated with hyperparathyroidism, PTH increases bone formation and resorption with a net efflux of calcium from bone. Sudden withdrawal of PTH in such patients causes an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption and perhaps other changes affecting calcium fluxes, leading to a marked net increase in bone uptake of calcium, phosphate, and magnesium. Thus, the hungry bone syndrome requires an abrupt decrease in PTH release that upsets the equilibrium between calcium efflux from bone and influx into the skeleton during bone remodeling.

Diagnosis of Hungry Bone Syndrome Persistently low serum calcium following parathyroidectomy Low or low normal serum phosphate Rising/raised serum alkaline phosphatase Low urine calcium These are the markers of increased bone formation after the sudden withdrawal of PTH. Serum raised alkaline phosphatase is secondary to increased osteoblastic activity. Urinary calcium and phosphate concentrations are reduced, indicating total body deficiency.

Treatment Elemental Calcium Vitamin D Calcium gluconate Calcium carbonate Vitamin D Elemental calcium 100–300 mg (10–30 ml of 10% calcium gluconate) diluted in 150 ml of five percent dextrose solution should be administered over ten minutes. If calcium gluconate is not available, calcium carbonate can be used. Calcium can also be diluted in isotonic saline or water but should not be used undiluted, as concentrated solutions can cause thrombophlebitis. The intravenous calcium solution must not also contain bicarbonate or phosphate, which can form insoluble calcium salts. Such regimens do not increase serum calcium for more than two hours, and should therefore be followed by a continuous infusion of elemental calcium 0·5–1·5 mg/Kg/hour (1 mmol ten per cent calcium gluconate is equivalent to 10 mg of elemental calcium). The intravenous calcium infusion should be continued until the patient is asymptomatic and tolerating oral calcium and vitamin 1,25 (OH)2D (calcitriol). Calcitriol is the preferred vitamin D preparation as the conversion of 25 to 1,25 (OH)2D requires 1α hydroxylation in the kidney, which is mediated by parathyroid hormone. In hungry bone syndrome, with the sudden withdrawal of parathyroid hormone, the activity of this enzyme is minimal. Since bone mineral density has been noted to increase for one year after successful parathyroidectomy, it is prudent to continue calcium supplementation for one year. Frequent measurements of urinary calcium are important to avoid progression of hypocalcaemia, to detect hypercalciuria and to guide adjustment of calcium and vitamin D therapy. When significant hypomagnesaemia is associated with hypocalcaemia, it is best treated using the parenteral route. Up to 50 mmol/day can be administered safely in a patient with normal renal function. A large fraction of parenterally administered magnesium may be excreted in the urine, even in the presence of profound total body deficiency. In hungry bone syndrome, hypomagnesaemia is usually corrected with the correction of hypocalcaemia. In cases of hypophosphataemia, intravenous phosphate is avoided since phosphate can combine with calcium to produce a further drop in serum calcium concentration. An exception to this rule is the presence of severe hypophosphataemia (less than 0·31mmol/L) where phosphate supplementation is necessary. The phosphate should be replaced by oral, intravenous or intraperitoneal routes in patients on dialysis.

Can Pamidronate Prevent Hungry Bone Syndrome After parathyroidectomy? Bisphosphonates may be beneficial in preventing hungry bone syndrome by reducing bone formation First report involved a 62-year-old woman with severe hyperparathyroidism who received 60 mg of pamidronate prior to parathyroidectomy. Another study retrospectively reviewed medical records to determine the effect of pre-operatively administered bisphosphonates on serum calcium levels following parathyroidectomy. Out of 14 patients who did not have hungry bone syndrome 6 had received bisphosphonates prior to surgery. Yuriy Gurevich, DO, and Leonid Poretsky, MD:Can Pamidronate Prevent Hungry Bone Syndrome after Parathyroidectomy, a case report

Current Status of the Patient: On Dialysis thrice a week On maintenance medications Still no match for kidney transplant

Thank You!